| Identification | Back Directory | [Name]
Lambrolizumab | [CAS]
1374853-91-4 | [Synonyms]
Lambrolizumab
Pembrolizumab
pembrolimumab
Pembrolizumab 25mg/ml
Pembrolizumab (anti-PD-1)
PEMBROLIMUMAB PD-1 1374853-91-4 | [EINECS(EC#)]
807-012-2 | [MDL Number]
MFCD02095740 |
| Hazard Information | Back Directory | [Uses]
A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. | [Mechanism of action]
Pembrolizumab is a humanized monoclonal IgG4 kappa antibody directed against human cell surface PD-1 (programmed death receptor-1) on lymphocytes. The PD-1 receptor provides a critical “immune checkpoint,” which helps prevent the immune system from attacking itself. Certain tumors have a high expression of PD-L1(programmed death receptor ligand-1). Other tumor types use adaptive immune resistance, which takes the natural physiology of PD-L1 induction (protection of immune-mediated damage from infections) and adapts it to anti-tumor responses. When PD-L1 engages with PD-1, the T-cell function becomes inhibited; pembrolizumab blocks the PD-1: PDL-1 complex formation, allowing improved T-cell mediated killing[1-2].
| [Clinical Use]
Humanised monoclonal antibody:
Treatment of advanced melanoma
Treatment of non-small cell lung carcinoma (NSLC)
Treatment of relapsed or refractory classical
Hodgkin lymphoma (cHL)
Treatment of urothelial carcinoma | [Enzyme inhibitor]
This humanized receptor-directed monoclonal antibody and anticancer
agent (MW = 146.3 kDa; CAS 1374853-91-4), also known by its code
name MK-3475, its former name lambrolizumab, and its trade name
Keytruda®, targets the Programmed Death-1 (PD-1 or Pdcd1) receptor, a
well-known negative regulator of T-cell effector mechanisms that limits
immune responses against cancer. Having received "Breakthrough Therapy"
designation in April, 2013 to expedite its development as a melanoma
therapy, pembrolizumab won final FDA approval in September, 2014.
Mechanism of Inhibitor Action: An immunoreceptor belonging to the
CD28/CTLA-4 family, PD-1 negatively regulates antigen receptor signaling
by recruiting the protein tyrosine phosphatase SHP-2, after interacting with
either of two ligands, PD-L1 or PD-L2. With its wide range of ligand
distribution in the body, PD-1 is significant in nearly every aspect of
immune responses (e.g. autoimmunity, tumor immunity, infectious
immunity, transplantation immunity, allergy and immunological privilege).
Pembrolizumab blocks the interaction between PD-1 and its ligands, PD-L1
and PD-L2. PD-1 and related target PD-ligand 1 (PD-L1) are normally
expressed on the surface of activated T cells, and formation of the PD-
L1·PD-1 complex inhibits immune activation and reduces T-cell cytotoxic
activity when bound. This negative feedback loop maintains normal
immune responses by limiting T-cell activity and thereby protecting normal
cells during chronic inflammation. Tumor cells can circumvent T-cell–
mediated cytotoxicity by expressing PD-L1 on their outer surface or on
tumor-infiltrating immune cells to inhibit immune-mediated tumor cell
killing. Use of pembrolizumab is indicated in the treatment of patients with
unresectable or metastatic melanoma and disease progression following
ipilimumab, especially if positive for the BRAFV600 mutation. MK3475 is
also highly selective, humanized monoclonal IgG4-k isotype antibody
against PD-1 that is designed to block the negative immune regulatory
signaling of the PD-1 receptor on T cells. Inhibitor Design: To prepare
pembrolizumab, the variable region sequences of a very high affinity (Kd =
28 pM) mouse anti-human PD-1 antibody were grafted into a human IgG4
immunoglobulin with a stabilizing Ser-228-Pro alteration in Fc receptors.
The IgG4 subtype does not engage Fc receptors and does not activate
complement, thereby avoiding cytotoxic effects of the antibody when it
binds to the T cells that it is intended to activate. Pharmacokinetics: The
recommended dose (2 mg/kg) is administered as an intravenous infusion
over 30 minutes every 3 weeks, or until disease progression resumes or
toxicity becomes unacceptable. Its steady-state concentration is reached by
18 weeks. (Half-life: 26 days; Clearance: 0.22 L/day) | [Drug interactions]
Potentially hazardous interactions with other drugs
Vaccines: risk of generalised infections with live
vaccines - avoid. | [Metabolism]
Pembrolizumab undergoes catabolism to small peptides
and single amino acids via general protein degradation
routes and does not rely on metabolism for clearance. | [storage]
Store at -80°C | [References]
[1] “Pembrolizumab Is Safe and Effective in Kaposi Sarcoma.” Cancer discovery (2022): 1183.
[2] Sidaway, Peter. “Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer.” Nature Reviews Clinical Oncology 40 1 (2024).
|
|
|